Suppr超能文献

源自人尿胰蛋白酶抑制剂的酸稳定纤溶酶抑制剂的多种分子形式。

Multiple molecular forms of acid-stable plasmin inhibitor derived from human urinary trypsin inhibitor.

作者信息

Sumi H, Toki N, Takasugi S, Maehara S, Tsushima H, Akazawa K, Mihara H

出版信息

Enzyme. 1983;30(4):252-8. doi: 10.1159/000469585.

Abstract

It was found that cyanogen bromide (BrCN) treatment of the highly purified human urinary trypsin inhibitors (H-UTI; specific activity 1,897 U/mg protein, and L-UTI; specific activity 1,850 U/mg protein) readily produced new plasmin inhibitors with almost no loss of UTI activity. Five multiple forms of chemically cleaved inhibitors (UTIB-I, UTIB-II, UTIB-III, UTIB-IV and UTIB-V) could be isolated from BrCN-treated L-UTI by isoelectric focusing and gel filtration. These inhibitors were very acid-stable and their isoelectric points (pI) were 4.5, 4.6, 4.9, 5.1 and 6.4, respectively. The molecular weights by SDS-polyacrylamide gel electrophoresis were almost the same at about 23,000 +/- 3,000. Although these inhibitors showed both anti-plasmin and anti-trypsin activities, much higher anti-plasmin/anti-trypsin activities were observed in the cleaved inhibitors than in the parent UTI. They competitively inhibited human plasmin with Ki values of 3.0-4.1 X 10(-8) mol/l (H-D-Val-Leu-Lys-pNA substrate).

摘要

结果发现,用溴化氰(BrCN)处理高度纯化的人尿胰蛋白酶抑制剂(H-UTI;比活性为1897 U/mg蛋白质)和L-UTI(比活性为1850 U/mg蛋白质),很容易产生新的纤溶酶抑制剂,而UTI活性几乎没有损失。通过等电聚焦和凝胶过滤,可从经BrCN处理的L-UTI中分离出五种化学裂解抑制剂的多种形式(UTIB-I、UTIB-II、UTIB-III、UTIB-IV和UTIB-V)。这些抑制剂对酸非常稳定,其等电点(pI)分别为4.5、4.6、4.9、5.1和6.4。通过SDS-聚丙烯酰胺凝胶电泳测定的分子量几乎相同,约为23000±3000。虽然这些抑制剂同时具有抗纤溶酶和抗胰蛋白酶活性,但在裂解抑制剂中观察到的抗纤溶酶/抗胰蛋白酶活性比母体UTI中的高得多。它们以3.0 - 4.1×10(-8) mol/l的Ki值竞争性抑制人纤溶酶(H-D-缬氨酸-亮氨酸-赖氨酸-pNA底物)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验